Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 7/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211826 | 0.80 | KMT2A (0.40) | LMNAPOLBKMT2AMAPT | |
| SCHEMBL18763028 | 0.79 | TGM2 (0.43) | TGM2MAOAMAOBF13A1LMNA | |
| SCHEMBL12038215 | 0.78 | ALDH1A1 (0.47) | LMNAPOLBKMT2AMAPT | |
| SCHEMBL19089490 | 0.77 | MAPT (0.50) | TGM2KMT2AMAPTBTK | |
| SCHEMBL11037348 | 0.74 | RORC (0.46) | TGM2LMNARORCMAPK1POLB | |
| SCHEMBL5078477 | 0.74 | MEN1 (0.61) | TGM2LMNAKMT2AMAPT | |
| SCHEMBL31162339 | 0.74 | MEN1 (0.61) | TGM2LMNAKMT2AMAPT | |
| SCHEMBL21894170 | 0.74 | TGM2 (0.58) | TGM2LMNAPOLBKMT2AMAPK3 | |
| SCHEMBL31162390 | 0.74 | TGM2 (0.58) | TGM2LMNAPOLBKMT2AMAPK3 | |
| SCHEMBL23293735 | 0.72 | TGM2 (0.47) | TGM2MAOAMAOBF13A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010489-B1 | DIALKYLPHENYL COMPOUNDS HAVING 2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8134006-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2010490-B1 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | THERAVANCE INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110086881-A1 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | THERAVANCE, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-7880010-B2 | form 1 of crystalline free base of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester; useful for treating pulmonary disorders, such as asthma and chronic obstructive pulmonary disease | THERAVANCE, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687521-B2 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-09 | — | — | US | disclosed |
| US-7524965-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-25 | — | — | US | disclosed |
| US-20070249674-A1 | Crystalline forms of a dimethylphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249674-A1 | Crystalline forms of a dimethylphenyl compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, PKD1 | TGM2 2281/4885MAOA 2449/4885MAOB 1149/4885 |
| US-20110086881-A1 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, PKD1 | TGM2 2281/4885MAOA 2449/4885MAOB 1149/4885 |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | TGM2 3826/4885MAOA 918/4885MAOB 814/4885 |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | TGM2 3826/4885MAOA 918/4885MAOB 814/4885 |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB2, ADRB1, ADRA2C | TGM2 3826/4885MAOA 918/4885MAOB 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.